Cytokines and the mechanisms of action of vaccine adjuvants

Cytokines, Cellular and Molecular Therapy

Volumn 3, Issue 4, 1997, Pages 233-246

  Brewer, James M ^a   Alexander, James ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Cytokine; Macrophage; Th1; Th2; Vaccine, adjuvant

Indexed keywords

ADJUVANT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; CONTROLLED STUDY; DRUG DESIGN; HELPER CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYTOKINES; HUMANS; MACROPHAGES; VACCINES;

EID: 0030687891     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Milich DR, Synthetic T and B cell recognition sites: implication for vaccine development. In: Advances in Immunology (ed FJ Dixon) 195-282. Academic Press, San Diego, 1989.
2. Ellis RW, The new generation of recombinant viral subunit vaccines. Curr Opin Biotech (1996) 7: 646-52.
3. Bomford R, Adjuvants for antiparasite vaccines. Parasitol Today (1989) 5: 41-6.
4. Moxton ER, Rappuoli R, Modern vaccines: Haemophilus influenzae infections and whooping cough. Lancet (1992) 335: 1324-8.
5. Strebel PM, Sutter RW, Cochi SL et al, Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 14: 568-79.
6. Rosen FS, Steiner LA, Unanue ER, Dictionary of Immunology. Macmillan, London, 1989.
7. Glenny AT, Pope CG, Waddington H et al, Immunological notes. XXIII The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol (1926) 29: 38-9.
8. Kersten GFA, Crommelin DJA, Liposomes and ISCOMs as vaccine formulations. Biochim Biophys Acta (1995) 1241: 117-38.
9. Alexander J, Brewer JM, Adjuvants and their modes of action. Livestock Production Sci (1994) 42: 153-62.
10. Bomford R, The comparative selectivity of adjuvants for humoral and cell mediated immunity. Clin Exp Immunol (1980) 39: 435-41.
11. Lindblad EB, Aluminium adjuvants. In: The Theory and Practical Application of Adjuvants (ed DES Stewart-Tull) 21-36. Wiley, Chichester, 1994.
12. Tascon RE, Colston MJ, Ragno S et al, Vaccination against tuberculosis by DNA injection. Nature Med (1996) 2: 888-92.
13. Clerici M, Shearer GM, The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today (1994) 15: 575-81.
14. Boersma WJA, Bogaerts WJC, Bianchi ATJ et al, Adjuvant properties of stable water-in-oil emulsions: evaluation of the experience with Specol. Res Immunol (1992) 143: 503-12.
15. Claassen E, de Leeuw W, de Greeve P et al, Freund's complete adjuvant: an effective but disagreeable formula. Res Immunol (1992) 143: 478-83.
16. Parish CR, Liew FY, Immune response to chemically modified Flagellin. III. Enhanced cell mediated immunity during high and low zone antibody tolerance to Flagellin. J Exp Med (1972) 135: 298-311.
17. Mosmann TR, Cherwinski H, Bond MW et al, Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136: 2348-57.
18. Cher DJ, Mosmann TR, Two types of murine helper T cell clone. 2. Delayed type hypersensitivity is mediated by Th1 clones. J Immunol (1987) 138: 3688-94.
19. Boom WH, Liano D, Abbas AK, Heterogeneity of helper/inducer T lymphocytes. 2 Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes. J Exp Med (1988) 167: 1352-63.
20. Mosmann TR, Coffman RL, Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 7: 145-73.
21. Rocken M, Saurat JH, Hauser C, A common precursor for CD4+ T cells producing IL-2 or EL-4. J Immunol (1992) 148: 1031-6.
22. Glenny AT, Buttle GAH, Stevens MF, Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J Pathol Bacteriol (1931) 34: 267-75.
23. Herbert WJ, Antigenicity of soluble protein in the presence of high levels of antibody: a possible mode of action of the antigen adjuvants. Nature (1966) 210: 747-8.
24. Herbert WJ, The mode of action of mineral oil emulsion adjuvants on antibody production in mice. Immunology (1968) 14: 301-18.
25. Freund J, The mode of action of immunological adjuvants. Adv Tuberc Res (1956) 7: 130-48.
26. Lascelles AK, Eagleson G, Beh KJ et al, Significance of Freund's adjuvant/antigen injection granuloma in the maintenance of serum antibody response. Vet Immunol Immunopathol (1989) 22: 15-27.
27. Freund J, Lipton MM, Experimental allergic encephalomyelitis after the excision of the injection site of antigen-adjuvant emulsion. J Immunol (1955) 75: 454-9.
28. Tew JG, Phipps RP, Mandel TE, The maintenance and regulation of the humoral immune response: persisting antigen and the role of follicular antigen-binding dendritic cells as accessory cells. Immunol Rev (1980) 53: 175-201.
29. World Health Organization, Immunological Adjuvants. WHO Technical Report, Series 595, 1976,
30. Allison AC, Gregoriadis G, Liposomes as immunological adjuvants. Nature (1974) 252: 252.
31. O'Hagan DT, McGee JP, Holmgren J et al, Biodegradable microparticles for oral immunization. Vaccine (1993) 11: 149-54.
32. Eldridge JH, Staas JK, Tice TR et al, Biodegradable poly(DL-lactide-co-glycolide) microspheres. Res Immunol (1992) 143: 557-63.
33. Morein B, Sundquist B, Hoglund S et al, ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature (1984) 308: 457-9.
34. Hunter RL, Strickland F, Kezdy F, The adjuvant activity of nonionic block polymer surfactants. I. The role of the hydrophile-lipophile balance. J Immunol (1981) 127: 1244-50.
35. Hunter RL, Bennett B, The adjuvant effect of nonionic block polymer surfactants. 2. Antibody formation and inflammation related to the structure of triblock and octablock copolymer. J Immunol (1984) 133: 3167-75.
36. Brewer JM, Alexander J, The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology (1992) 75: 570-5.
37. Brewer JM, Roberts CW, Conacher M et al, An adjuvant formulation which preferentially induces Th1 cytokine and CD8+ cytotoxic responses is associated with up-regulation of EL-12 and suppression of EL-10 production. Vaccine Res (1996) 5: 77-89.
38. Harding CV, Song R, Phagocytic processing of exogenous paniculate antigens by macrophages for presentation by class I MHC molecules. J Immunol (1994) 153: 4925-33.
39. Gregoriadis G, Immunological adjuvants: a role for liposomes. Immunol Today (1990) 11: 89-97.
40. Mannhalter JW, Neychev HO, Zlabinger CJ et al, Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol (1985) 61: 143-51.
41. Francis MJ, Fry CM, Rowlands DJ et al, Immunological priming with synthetic peptides of foot-and-mouth disease virus. J Gen Virol (1985) 66: 2347-54.
42. Beatty JD, Beatty B, Paraskevas F, Liposome stimulation of anti-BSA antibody production in mice. J Surg Res (1981) 31: 259-67.
43. Shek PN, Lukovitch S, The role of macrophages in promoting the antibody response mediated by liposome associated protein antigens. Immunol Lett (1982) 5: 305-9.
44. Carayanniotis G, Barber BH, Characterization of the adjuvant free serological response to protein antigens coupled to antibodies specific for class II MHC determinants. Vaccine (1990) 8: 137-44.
45. DalMonte PR, Szoka FC, Antigen presentation by B cells and macrophages of cytochrome c and its antigenic fragment when conjugated to the surface of liposomes. Vaccine (1989) 7: 401-8.
46. DalMonte PR, Szoka FC, Effect of liposome encapsulation on antigen presentation in vitro: comparison of presentation by peritoneal macrophages and B cell tumors. J Immunol (1989) 142: 1437-43.
47. Rabinovitch M, Professional and non-professional phagocytosis: an introduction. Trends Cell Biol (1995) 5: 85-8.
48. Abbas AK, Williams ME, Burstein HJ et al, Activation and functions of CD4+ T cell subsets. Immunol Rev (1991) 123: 5-22.
49. Gajewski TF, Pinnas M, Wong T et al, Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen presenting cell populations. J Immunol (1991) 146: 1750-8.
50. Gajewski TF, Fitch FW, Differential activation of murine Th1 and Th2 clones. Res Immunol (1991) 142: 19-23.
51. Schmitz J, Radbruch A, Distinct antigen presenting cell derived signals induce Th cell proliferation and expression of effector cytokines. Int Immunol (1992) 4: 43-51.
52. Hayakawa K, Hardy RR, Murine CD4+ subsets defined J Exp Med (1988) 168: 1825-38.
53. Sacks DL, Scott PA, Asofsky R et al, Cutaneous leishmaniasis in anti IgM treated mice: enhanced resistance due to functional depletion of a B cell dependent T cell involved in a suppressor pathway. Nature (1984) 132: 2072-7.
54. Fong TAT, Mosmann TR, The role of IFNγ in delayed type hypersensitivity mediated by Th1 clones. J Immunol (1989) 143: 2887-93.
55. Finkelman FD, Snapper CM, Mountz JD et al, Polyclonal activation of the murine immune system by a goat antibody to mouse IgD. 9. Induction of a polyclonal IgE response. J Immunol (1987) 138: 2826-30.
56. Champion BR, Buckham S, Page K et al, Secondary immunoglobulin responses of BALB/c mice previously stimulated with goat anti mouse IgD. Immunology (1991) 72: 336-13.
57. Day MJ, Tse AGD, Puklavec M et al, Targeting autoantigen to B cells prevents the induction of a cell mediated autoimmune disease in rats. J Exp Med (1992) 175: 655-9.
58. Bogen SA, Fogelman I, Abbas AK, Analysis of EL-2, IL-4 and IFNγ producing cells in situ during immune responses to protein antigens. J Immunol (1993) 150: 4197-205.
59. Bogen SA, Weinberg DS, Abbas AK, Histological analysis of T lymphocyte activation in reactive lymph nodes. J Immunol (1991) 147: 1537-41.
60. van Rooijen N, Liposomes as an in vivo tool to study and manipulate macrophage function. Res Immunol (1992) 143: 177-256.
61. van Rooijen N, The liposome mediated macrophage 'suicide' technique. J Immunol Meth (1989) 124: 1-6.
62. Brewer JM, Richmond J, Alexander J, The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies. Clin Exp Immunol (1994) 97: 164-71.
63. Philips NC, Emili A, Enhanced antibody responses to liposome associated protein antigens: preferential stimulation of IgG2a/b production. Vaccine (1992) 10: 151-8.
64. Bennett B, Check IJ, Olsen MR et al, A comparison of commercially available adjuvants for use in research. J Immunol Meth (1992) 153: 31-40.
65. Maloy KJ, Donachie AM, Mowat AM, Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMs. Eur J Immunol (1995) 25: 2835-11.
66. Yang X, Gieni RS, Mosmann TR et al, Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo J Exp Med (1993) 178: 349-53.
67. HayGlass HT, Stefura WP, Antigen specific inhibition of ongoing murine IgE responses. 2. Inhibition of IgE responses induced by treatment with glutaraldehyde modified allergens is parallelled by reciprocal increases in IgG2a synthesis. J Immunol (1991) 147: 2455-60.
68. Harding CV, Collins DS, Kanagawa O et al, Liposome encapsulated antigens engender lysosomal processing for class II presentation and cytostolic processing for class I presentation. J Immunol (1991) 147: 2860-3.
69. Hale AH, Ruebush MJ, Harris DT, Study of the minimal molecular and cellular requirements for elicitation of anti vesicular syomatitis virus cytotoxic T cells using purified viral and cellular antigens incorporated into phospholipid vesicles. In: Liposomes and Immunobiology (ed BH Tom, HR Six) 211-24. Elsevier, Amsterdam, 1980.
70. Zhou F, Rouse BT, Huang L, Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J Immunol (1992) 149: 1599-604.
71. Heeg K, Kuon W, Wagner H, Vaccination of class I restricted murine CD8+ cytotoxic lymphocytes towards soluble antigens: ISCOM-OVA complexes enter the class I MHC restricted antigen pathway and allow sensitisation against the immunodominant peptide. Eur J Immunol (1991) 21: 1523-7.
72. Zhou F, Huang L, Delivery of protein antigen to the major histocompatibility complex class I restricted presentation pathway, J Drug Target (1995) 3: 91-109.
73. Spitznagel JK, Allison AC, Mode of action of adjuvants: effects on antibody responses to macrophage-associated bovine serum albumin. J Immunol (1970) 104: 128-39.
74. Unanue ER, Askonas BA, Allison AC, A role of macrophages in the stimulation of immune responses by adjuvants. J Immunol (1969) 103: 71-8.
75. Dinarello CA, Cytokines: interleukin-1 and tumor necrosis factor (cachectin). In: Inflammation: Basic Principles and Clinical Correlates (ed JI Gallin, IM Goldstein, R Snyderman) 195-208. Raven Press, New York, 1988.
76. Di Giovine FS, Duff GW, Interleukin 1: the first interleukin. Immunol Today (1990) 11: 13-20.
77. Van Snick J, Interleukin-6: an overview. Annu Rev Immunol (1990) 8: 253-78.
78. D'Andrea A, Rengaraju M, Valiante NM et al, Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med (1992) 176: 1387-98.
79. Beutler B, Cerami A, The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol (1989) 7: 625-55.
80. Lichtman AH, Chin J, Schmidt JA et al, Role of interleukin 1 in the activation of T lymphocytes. Proc Natl Acad Sci USA (1988) 85: 9699-703.
81. Reed SG, Pihl DL, Cordon PJ et al, LL-1 as adjuvant. Role of T cells in augmentation of specific antibody production by recombinant human IL-1 alpha. J Immunol (1989) 142: 3129-33.
82. Heath AW, Devey ME, Brown IN et al, Interferon-gamma as an adjuvant in immunocompromised mice. Immunology (1989) 67: 520-4.
83. Staruch MJ, Wood DD, The adjuvanticity of interleukin 1 in vivo. J Immunol (1983) 130: 2191-4.
84. Blecha F, Reddy DN, ChitkoMcKown CG et al, Influence of recombinant bovine interleukin-1beta and interleukin-2 in pigs vaccinated and challenged with Streptococcus suis. Vet Immunol Immunopathol (1995) 44: 329-46.
85. Tagliabue A, Boraschi D, Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163-171. Vaccine (1993) 11: 594-5.
86. Wood DD, Staruch MJ, Durette PL et al, Role of IL-1 in muramyl dipeptide adjuvanticity in vivo. Cell Immunol (1982) 70: 407.
87. Oppenheim JJ, Togawa A, Chedid L et al, Components of mycobacteria and muramyl dipeptide with adjuvant induce lymphocyte activating factor. Cell Immunol (1980) 50: 71-81.
88. Sagara TA, Mori S, Ohkawara S et al, A limited role of IL-1 in immune-enhancement by adjuvants. Immunology (1990) 71: 251-7.
89. Grun JL, Maurer PH, Different T helper cell subsets elicited in mice utilising two different adjuvant vehicles: the role of endogenous IL-1 in proliferative responses. Cell Immunol (1989) 121: 134-45.
90. Tartaglia LA, Goeddel DV, Two TNF receptors. Immunol Today (1992) 13: 151-3.
91. Erickson SL, Desauvage FJ, Kikly K et al, Decreased sensitivity to tumor necrosis factor but normal T-cell development in TNF-receptor-2 deficient mice. Nature (1994) 372: 560-3.
92. Thomas B, Grell M, Pfizenmaier K et al. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med (1990) 172: 1019-23.
93. Rothe J, Lesslauer W, Lotscher H et al, Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF mediated toxicity but highly susceptible to infection with Listeria monocytogenes. Nature (1993) 364: 798-802.
94. Adams JL, Czuprynski CJ, Mycobacterial cell wall components induce the production of TNF-alpha, EL-1, and EL-6 by bovine monocytes and the murine macrophage cell line RAW 264.7. Microb Pathogenesis (1994) 16: 401-11.
95. Leclerc C, Vogel F, Synthetic immunomodulators and synthetic vaccines. Crit Rev Ther Drug Carrier Syst (1986) 2: 353-406.
96. Parant M, Influence of synthetic adjuvants on nonspecific resistance to infections. Int J Immunopharmacol (1994) 16: 445-9.
97. Schijns V, Claassen I, Vermeulen AA et al, Modulation of antiviral immune responses by exogenous cytokines: effects of tumour necrosis factor-alpha, interleukin-1 alpha, interleukin-2 and interferon-gamma on the immunogenicity of an inactivated rabies vaccine. J Gen Virol (1994) 75: 55-63.
98. Brewer JM, Conacher M, Gaffney M et al, Neither IL-6 nor signalling via TNFR1 contribute to the adjuvant activity of alum and Freund's adjuvant. Immunol (in press).
99. Valensi JPM, Carlson JR, Van NGA, Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol (1994) 153: 4029-39.
100. van Ommen R, Vredendaal AECM, de Gooyer M et al, The effect of IFNγ, alum and complete Freund's adjuvant on TNP-KLH induced IgG1, IgE and IgG2a responses in mice. Mediators of Inflammation (1994) 3: 387-92.
101. Duits AJ, Van Puijenbroek A, Vermeulen H et al, Immunoadjuvant activity of a liposomal IL-6 formulation. Vaccine (1993) 11: 777-81.
102. Kopf M, Baumann H, Freer G, et al, Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 368: 339-42.
103. Romani L, Mencacci A, Cenci E et al, Impaired neurophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med (1996) 183: 1345-55.
104. Romani L, Puccetti P, Bistoni F, Biological role of Th cell subsets in candidiasis. Chem Immunol (1996) 63: 115-37.
105. Dalrymple SA, Lucian LA, Slattery R et al, Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun (1995) 63: 2262-8.
106. Kishimoto T, The biology of interleukin-6. Blood (1989) 74: 1-10.
107. Kopf M, Le Gros G, Coyle AJ et al, Immune responses of IL-4, IL-5, IL-6 deficient mice. Immunol Rev (1995) 148: 45-69.
108. MacLennan ICM, Germinal centers. Annu Rev Immunol (1994) 12: 117-39.
109. Gupta RK, Relyveld EH, Lindblad EB et al, Adjuvants - a balance between toxicity and adjuvanticity. Vaccine (1993) 11: 293-306.
110. Hsieh C-S, Macatonia SE, Tripp CS et al, Development of Th1 CD4+ T cells through IL-12 produced by Listeria induced macrophages. Science (1993) 260: 547-9.
111. Scott P, IL-12: initiation cytokine for cell-mediated immunity. Science (1993) 260: 496-7.
112. Germann T, Gately MK, Schoenhaut DS et al, Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol (1993) 23: 1762-70.
113. Morris SC, Madden KB, Adamovicz JJ et al, Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol (1994) 152: 1047-56.
114. Schmitt E, Hoehn P, Huels C et al, T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-γ and is inhibited by transforming growth factor-β. Eur J Immunol (1994) 24: 793-8.
115. Kennedy MK, Picha KS, Shanebeck KD et al, Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol (1994) 24: 2271-8.
116. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 170: 827-45.
117. Croft M, Carter L, Swain SL, et al, Generation of polarized antigen specific CD8 effector populations: reciprocal action of interleukin (EL)-4 and EL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med (1994) 180: 1715-28.
118. Heinzel FP, Schoenhaut DS, Rerko RM et al, Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med (1993) 177: 1505-9.
119. Sypek JP, Chung CL, Mayor SEH et al, Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med (1993) 177: 1797-802.
120. Kiniwa M, Gately M, Gubler U et al, Recombinant interleukin-12 suppresses the synthesis of immunoglobulin-E by interleukin-4-stimulated human lymphocytes. J Clin Invest (1992) 90: 262-6.
121. King CL, Hakimi J, Shata MT et al, IL-12 regulation of parasite antigen-driven IgE production in human helminth infections. J Immunol (1995) 155: 454-61.
122. Manetti R, Gerosa F, Giudizi MG et al, Interleukin 12 induces stable priming for interferon gamma (IFNγ) production during differentiation of human T helper (Th) cells and transient IFNγ production in established Th2 cell clones. J Exp Med (1994) 179: 1273-83.
123. Bliss J, Van Cleave V, Murray K et al, IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol (1996) 156: 887-94.
124. Marshall JD, Secrist H, DeKruyff RH et al, IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+ T lymphocytes. J Immunol (1995) 155: 111-7.
125. Afonso LCC, Scharton TM, Vieira LQ et al, The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science (1994) 263: 235-7.
126. Wynn TA, Cheever AW, Jankovic D et al, An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature (1995) 376: 594-6.
127. Macatonia SE, Hsieh C-S, Murphy KM et al, Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFNγ production is IFNγ dependent. Int Immunol (1993) 5: 1119-28.
128. Inaba K, Inaba M, Naito M et al, Dendritic cell progenitors phagocytose particulates, including Bacillus Calmette-Guérin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med (1993) 178: 479-88.
129. Reis e Sousa C, Stahl PD, Austyn JM, Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med (1993) 178: 509-19.
130. Scheicher C, Mehlig M, Dienes HP et al, Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1 alpha and interleukin-12 p40/p35 and triggers prolonged, efficient presentation. Eur J Immunol (1995) 25: 1566-72.
131. Macatonia SE, Hosken NA, Litton M et al, Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol (1995) 154: 5071-9.
132. Guidos C, Wong M, Lee K, A comparison of the stimulatory activities of lymphoid dendritic cells and macrophages in T proliferative responses to various antigens. J Immunol (1984) 133: 1179-84.
133. Brewer JM, Alexander J, Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant driven IgG2a production independent of MHC control. Vaccine (1994) 12: 613-19.
134. Roberts CW, Brewer JM, Alexander J, Congenital toxoplasmosis in the BALB/c mouse: prevention of vertical disease transmission and foetal death by vaccination. Vaccine (1994) 12: 1389-94.
135. Magram J, Connaughton SE, Warrier RR et al, IL-12-deficient mice are defective in IFNgamma production and type 1 cytokine responses. Immunity (1996) 4: 471-81.
136. Dighe AS, Campbell D, Hsieh CS et al, Tissue-specific targeting of cytokine unresponsiveness in transgenic mice. Immunity (1995) 3: 657-66.
137. Flesch IEA, Hess JH, Huang S et al, Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med (1995) 181: 1615-21.
138. Romagnani S, Induction of Th1 and Th2 responses: a key role for the 'natural' immune response. Immunol Today (1992) 13: 379-81.
139. Bendelac A, Mouse NK1+ T cells. Curr Opin Immunol (1995) 7: 367-74.
140. Kawase I, Brooks CG, Kuribayashi K et al, IL-2 induces gamma interferon production: participation of macrophages and NK-like cells. J Immunol (1983) 131: 288-92.
141. Gidlund M, Orn A, Wigzell H et al, Enhanced NK activity in mice injected with interferon and interferon inducers. Nature (1978) 273: 759-61.
142. Bancroft GJ, Schreiber RD, Unanue ER, Natural immunity: a T cell independent pathway of macrophage activation defined in the SCID mouse. Immunol Rev (1991) 124: 5-24.
143. Roncarolo M, Bigler M, Haanen JBA et al. Natural killer cells can efficiently process and present protein antigens. J Immunol (1991) 147: 781-7.
144. Wright MD, Wood PR, Coia G et al, Particulate antigens may be reprocessed after initial phagocytosis for presentation to T cells in vivo. Immunol Cell Biol (1987) 65: 505-10.
145. Heath AW, Playfair JHL, Conjugation of interferon gamma to antigen enhances its adjuvanticity. Immunology (1990) 71: 454-6.
146. Gajewski TF, Fitch FW, Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol (1988) 140: 4245-52.
147. Gajewski TF, Joyce J, Fitch FW, Anti-proliferative effect of IFNγ in immune regulation. 3. Differential selection of Th1 and Th2 murine helper T lymphocyte clones using recombinant IL-2 and IFNγ. J Immunol (1989) 143: 15-22.
148. Wang E, Michl J, Pfeffer LM et al, Interferon suppresses pinocytosis but stimulates phagocytosis in mouse peritoneal macrophages: related changes in cytoskeletel organization. J Cell Biol (1984) 98: 1328-41.
149. Steeg PR, Moore RN, Johnson HM et al, Regulation of murine macrophage Ia expression by a lymphokine with immune interferon activity. J Exp Med (1982) 156: 1780-93.
150. Mond JJ, Carman J, Sarme J et al, Interferonγ suppresses B cell stimulation factor (BSF-1) induction of class II MHC determinants on B cells. J Immunol (1986) 137: 3534-7.
151. Huang S, Hendriks W, Althage A et al, Immune-response in mice that lack the interferon-gamma receptor. Science (1993) 259: 1742-5.
152. Swain SL, Weinberg AD, English M et al, IL-4 directs the development of Th2 like helper effectors. J Immunol (1990) 145: 3796-806.
153. Swain SL, Regulation of the development of distinct subsets of CD4+ T cells. Res Immunol (1991) 142: 14-8.
154. Launois P, Ohteki T, Swihart K et al, In susceptible mice, Leishmania major induce very rapid interluekin-4 production by CD4+ T-cells which are NK1.1-. Eur J Immunol (1995) 25: 3298-307.
155. Kopf M, Le Gros G, Bachmann M et al, Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature (1993) 362: 245-8.
156. Brewer JM, Conacher M, Satoskar A et al, In interleukin-4 deficient mice, alum not only generates T helper-1 reponses equivalent to Freund's complete adjuvant, but continues to induce T helper-2 cytokine production. Eur J Immunol (1996) 26: 2062-6.
157. Gollob JA, Kawasaki H, Ritz J, Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur J Immunol (1997) 27: 647-52.
158. Hamaoka T, Katz DH, Bloch KJ et al, Hapten specific IgE antibody responses in mice. 1. Secondary IgE responses in irradiated recipients of syngeneic primed spleen cells. J Exp Med (1973) 138: 306-11.
159. Nixon George A, Moran T, Dionne G et al, The adjuvant effect of stearyl tyrosine on a recombinant subunit hepatitis B surface antigen. J Immunol (1990) 144: 4798-802.
160. Hassan Y, Brewer JM, Alexander J et al, Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Vaccine (1996) 14: 1581-9.
161. Takayama K, Olsen M, Datta P et al, Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors. Vaccine (1991) 9: 257-65.
162. 5: I. Effects of carrier, copolymer adjuvants, and lipopolysaccharide on isotype selection. J Immunol (1991) 146: 3583-90.